Bardoxolone displays potent activity against triple negative breast cancer by inhibiting the TRIP13/STAT3 circuit

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Triple-negative breast cancer (TNBC) presents significant treatment challenges with limited therapeutic targets.
• High expression of TRIP13 in breast cancer correlates with poor prognosis, but its precise role is unclear.

Purpose of the Study:

• To elucidate the mechanism by which TRIP13 influences TNBC progression.
• To investigate the potential of bardoxolone as a therapeutic agent targeting the TRIP13/STAT3 pathway in TNBC.

Main Methods:

• Investigated TRIP13's role in TNBC cell viability and migration.
• Analyzed the interaction between TRIP13 and STAT3 signaling.
• Assessed the efficacy of bardoxolone in inhibiting STAT3 activation and TRIP13 expression.
• Evaluated bardoxolone's effects on cancer cell proliferation, apoptosis, and in vivo tumor growth.

Main Results:

• TRIP13 significantly promotes TNBC cell viability and migration.
• TRIP13 activates STAT3, and this activation is part of a positive feedback loop where STAT3 upregulates TRIP13.
• Bardoxolone effectively inhibits STAT3 activation and downregulates TRIP13, leading to reduced proliferation, migration, and induced apoptosis in cancer cells.
• Bardoxolone suppressed TNBC tumor growth in vivo without observable toxicity.

Conclusions:

• The TRIP13/STAT3 signaling circuit is crucial for TNBC cell proliferation and survival.
• Targeting this circuit with bardoxolone demonstrates significant therapeutic potential for TNBC treatment.
• Bardoxolone represents a promising, non-toxic therapeutic strategy for managing triple-negative breast cancer.